<DOC>
	<DOCNO>NCT00441025</DOCNO>
	<brief_summary>The purpose study determine whether treatment Alemtuzumab combination CHOP ( cyclophosphamide , doxorubicin , vincristine prednisolone ) effective first line treatment patient peripheral T-cell lymphoma .</brief_summary>
	<brief_title>The Effectiveness Alemtuzumab Combination With CHOP Treat Patients Newly Diagnosed With PTCL</brief_title>
	<detailed_description>Peripheral T-cell lymphoma ( PTCL ) common Asia Europe United States ( 17-40 % vs. 5-10 % ) . Most study report poor prognosis PTCL compare B-cell non-Hodgkin 's lymphoma ( NHL ) . CHOP ( cyclophosphamide , doxorubicin , vincristine prednisolone ) currently regard standard chemotherapy regimen patient newly diagnose NHL . Alemtuzumab ( Campath-1H ) humanize monoclonal antibody target CD52 , cell surface protein present high density normal malignant B T lymphocytes.Malignant T cell express particularly high number CD52 cell surface marker ( approximately 500,000 molecules/lymphocytes ) , T-cell malignancy may thus particularly responsive alemtuzumab . As response rate tend high patient newly diagnose PTCL , study evaluate efficacy alemtuzumab combination CHOP administer up-front therapy patient newly diagnose PTCL term response rate overall survival .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Patients must diagnosis one follow histologic type accord WHO classification : Angioimmunoblastic Tcell lymphoma Extranodal NK/Tcell lymphoma , nasal type Enteropathytype Tcell lymphoma Hepatosplenic gammadelta Tcell lymphoma Subcutaneous panniculitislike Tcell lymphoma Anaplastic largecell lymphoma , T/null cell , primary systemic type Peripheral Tcell lymphoma , otherwise characterize Newly diagnose , age 1565 year . Complete work baseline evaluation measurement ( Appendix B ) Patient 's free write inform consent . Patients know hypersensitivity murine protein component alemtuzumab . Patients receive prior antilymphoma treatment chemotherapy radiotherapy Patients poor performance status ( PS ; ECOG criterion 34 ) ( Appendix C ) . Serologic evidence HCV HCV RNA chronic hepatitis . Serologic evidence HBV HBV RNA chronic hepatitis . Patients history impaired cardiac status myocardial infarction . Patients serum creatinine &gt; = 1.8 mg/dl , bilirubin &gt; = 1.5 time upper limit normal range , SGOT SGPT &gt; = 3 time upper limit normal range , unless due tumor involvement . Patients active uncontrolled infection , active nonmalignant gastric duodenal ulcer , uncontrolled diabetes mellitus severe medical condition would preclude aggressive cytotoxic chemotherapy . Active secondary malignancy . Pregnant lactating woman . Serious medical psychiatric illness prevent inform consent . Patients likely lose follow ( eg , unwilling difficult return , contact ) .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>MabCampath + CHOP PTCL</keyword>
</DOC>